Podcast: Driving DBS access for Parkinson's patients in the UK and Europe
Parkinson’s UK reports 166,000 patients in the UK and 2.2 million in Europe. WHO says it's the fastest-growing neurological disorder. Boston Scientific's survey of 60 HCPs found 88% believe DBS doesn't reach all UK patients who could benefit. The podcast discusses DBS access issues in the UK and Europe.
How this was made
The 30-second read
Why it matters
Boston Scientific's survey reveals a significant access gap, which could affect its neuromodulation business outlook.
Market read
The article provides limited new data on DBS market access, with modest relevance for investors in Boston Scientific.
What to watch
Potential upcoming reimbursement reforms or new competitor entries are not discussed.
Background
The podcast discusses Parkinson's disease prevalence, economic impact, and challenges in accessing deep-brain stimulation (DBS) therapy in the UK and Europe.
Ticker impact
Boston Scientific disclosed a survey showing 88% of UK HCPs believe DBS does not reach all eligible patients.
possible downside as investors weigh market penetration challenges
Survey highlights a market gap that could limit sales growth for Boston Scientific's DBS devices.
Market effects
Highlights access barriers in the neuromodulation market, may affect peers.
UK and Europe DBS adoption concerns could influence regional device sales forecasts.
Limited, as the issue is specific to DBS access rather than broad market moves.
Counterpoint
The survey may overstate barriers; actual adoption could improve with policy changes.
Key entities
- companyBoston Scientific
Medical device maker providing DBS systems.
- organizationParkinson's UK
Charity providing disease prevalence data.
